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Introduction
Since the emerging of novel Corona virus disease 2019 
(COVID-19) in December, 2019, this virus has affected 
nearly 160 million people and caused about 3.25 million 
deaths worldwide. In Iran, more than 245,000 people are 
affected which has lead to 11000 deaths in the country up 
to 7 July 2020 [1]. The symptoms of the COVID-19 are 
wide from asymptomatic to severe forms of pneumonia 
and multi organ failure [2-4]. Fever, cough, and fatigue 
are the most common symptoms of COVID-19  [2]. 
Case fatality rate is 3.8% and 25.6% of the patients 
experience the severe forms of the disease  [2,  5]. 
COVID-19 is a highly contagious disease. Human to 
human transmission is the main cause of COVID-19 
transmission and close contact with infected patients 
may transmit the virus to others  [6]. Secondary attack 
rate of this infection is about 35%  [7] and the virus 
spreads rapidly in populations. Rapid increase in the 
number of patients impose excess burden on the health 
care systems and increases the costs [8]. To enhance the 
patients’ care and to optimize utilizing medical resources 
during this pandemic, relevant biomarkers are needed 
for prediction of the disease’s progression and actively 
monitoring illness severity at the early stage [2, 3].There 
are several studies on the factors which can predict 
the outcome in patients with COVID-19. Old age, low 
levels of lymphocytes, high levels of C reactive protein 
(CRP) and cardiac troponin, and D-Dimers levels higher 
than 1  μg/L were associated with poor prognosis in 
China [4, 9-11]. In a systematic review by Wynants et al, 
age, sex, computed tomography (CT) findings, lactate 
dehydrogenase (LDH), CRP, lymphocytes count, and 
presence of comorbidities were associated with the 
prognosis  [12]. In previous studies on influenza, there 
had been differences between populations in the terms 
of the factors that have been related with mortality. 
Urea level in Mecedonia  [13], CRP in Tunisia, and 
Creatinine in Taiwan were associated with mortality 
in patients with influenza . Such may be applicable in 
Introduction. To enhance the COVID-19 patients’ care and 
to optimize utilizing medical resources during the pandemic, 
relevant biomarkers are needed for prediction of the disease’s 
progression. The current study was aimed to determine the fac-
tors that affect the mortality of COVID-19 patients admitted in 
Baharloo hospital in Iran.
Methods. in the current retrospective study, 56 survived 
patients and 56 patients who were died (a total of 112 cases) 
because of COVID-19 infection were randomly selected from 
those who were admitted to Baharloo hospital. Each patient 
who was diagnosed with COVID-19 and had recovered from 
it matched with each non-survived patient in the term of age. 
Laboratory tests of all these patients at the time of admission 
were recorded and compared. All analyses performed using 
spss version 22 by considering α = 0.05 as a significant level.
Results. There was no statistical difference in the age and gender 
distribution between the two groups (p > 0.05). The prevalence 
of diabetes among survived patients was 37.5% and among non-
survived patients was 26.8% and there was no statistical differ-
ence between two groups regarding this comorbidity (p = 0.22). 
Also, there was no statistical difference in the prevalence of 
hypertension and coronary heart diseases between two groups 
(p  >  0.05). Lymphocyte percentage, blood oxygen level, and 
platelet (PLT) count was significantly higher in patients who 
had recovered (P < 0.05).
Conclusions. LDH level, Lymphocyte percentage, PLT count, 
and blood Oxygen saturation have associations with severe 
forms of COVID-19 infection and can be used as predictors to 
assess the patients who are suspected of infection with COVID-
19 at the time of admission.
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patients with COVID-19 and there may be differences 
in prognostic factors in different populations. As there 
are no studies available on the prognostic factors of 
COVID-19 in Iranian population, the current study was 
aimed to determine the factors that affect the mortality 




Patients included in the current retrospective study 
were suspected of COVID-19 infection admitted in 
the Baharloo hospital. Baharloo hospital is a teaching 
hospital that located in Tehran and is affiliated to Tehran 
University of medical sciences medical school. This 
hospital has been COVID-19 referral center since the 
COVID-19 outbreak in Tehran. Inclusion criteria were: 
1) clinical symptoms of COVID-19 such as fever, cough, 
fatigue, myalgia, dyspnea, chest pain, nausea, vomiting; 
2)  positive nasopharynx COVID-19 polymerase chain 
reaction (PCR) test; 3)  lung imaging compatible with 
COVID-19 pneumonia. Patients who were diagnosed 
with bacterial pneumonia at the time of admission, those 
whose symptoms had started more than 7 days prior 
to admission and those whose medical records were 
incomplete were excluded from our study. 
From those who were eligible to be included in our study, 
56 patients who were died because of COVID-19 were 
randomly selected. Also the information of 56  patient 
who were recovered from the disease and were discharged 
from the hospital were selected as a control group. A 
code was dedicated to each patient and all data were 
recorded anonymously. We reviewed medical records of 
their recent admission because of COVID-19 infection. 
Demographic characteristics of patients such as age, 
gender, and their underlying diseases were recorded. 
Laboratory and clinical parameters such as blood’s O2 
Saturation, hemoglobin (Hb), white blood cell count 
(WBC), percentages of PMN and lymphocyte, platelet 
count, ESR, CRP, LDH, and serum vitamin D level at 
the time of admission to emergency department were 
extracted. The study design was approved by Tehran 
University of medical sciences ethical committee. 
 Statistical analysis 
The discriptive analysis was performed using the mean 
(Standard Deviation) or frequency and percent for 
quantitative and qualitative variables, respectively. The 
differences in characteristics between survived and non-
survived patients were examined using independent 
t-test for continuous variables and chi-squared test for 
categorical variables. All analysis performed using 
SPSS software version 22 by considering α = 0.05 as a 
significant level.
Laboratory analysis 
On the first admission day, 10 cc blood sample was 
obtained and sent to the hospital laboratory
for CBC-diff (WBC count, Lymphocyte and PMN 
percents, Platelet count), LDH, CRP, ESR, and Vitamin 
D3 level. The automated hematology analyzer, Sysmex 
KX-21N, was applied for CBC-diff which counted 
cells and collected information on their size and structure 
(Lymphocyte, Neutrophil, Platelet). ESR test was 
made by Therma NE instrument; however, sometimes 
the western green tubes were used for measurement 
of sedimentation rate manually. CRP measurement 
was performed by immunoturbidimetry method using 
Hitachi 912 and LDH level was performed by enzymatic 
method using Hitachi 717. Vitamin D3 level was 
measured by high performance liquid chromatography 
(HPLC) method using Agilent instrument.
Results
In total 56 survived and 56 non-survived patients 
included in our study. Of these patients, 77 (68.8%) were 
male and 35 (31.3%) were female. In survived group 38 
(67.9%) of cases were males and 18 (32.1%) of cases 
were females. In non-survived group 39 (69.6%) of cases 
were males and the 17 (30.4%) of cases were females. 
There was no significant difference in gender between 
two groups (P: 0.83).
The mean of ages among survived patients was 
67.14 ± 10.54 and among death cases was 67.96 ± 14.60. 
There was no significant difference between two groups 
about age distribution (P = 0.73).
The prevalence of diabetes among among survided 
and non- survided patients were 37.5% and 26.5% 
respectively. There was no statistical difference between 
two group about this comorbidity(p = 0.22).Also there 
was no statistical difference in prevalence of hypertention 
and coronary heart diseases between two groups. More 
information has been shown in Table I. 
Lymphocyte percentage was significantly higher in 
patients who had recovered from the disease as compared 
with the patients who died (22.76 vs 18%)(P = 0.001). 
PLT level in recovered patients was significantly higher 
than death cases (214,964 vs 167,196/microliter) 
(P  =  0.003). LDH level was significantly higher in 
those who had not survived from COVID-19 infection 
compared to those who had recovered (587 vs 487 
U/L) (P  <  0.001). Also, Blood oxygen saturation was 
significantly higher in patients who survived COVID-19 
compred to those who died (91 vs 82%)(P  <  0.001). 
The more information about the Laboratory and clinical 
measures status in survived and non-survived patients 
was shown in Table II.
Discussion
COVID-19 pneumonia sometimes progress rapidly to 
Acute respiratory distress syndrome (ARDS) and even 
death. Unfortunately, until now, there is no definite 
treatment for the COVID-19 related illnesses. The 
ADMISSION LABORATORY TESTS AND COVID-19 PROGNOSIS
E323
established laboratory markers to assess the illness 
severity are few and tentative [2, 14]. 
In the present study, some simple and available 
biomarkers are investigated and compared between 
survivor and non- survivor groups. Neutrophil and 
Lymphocyte counts, neutrophil to lymphocyte ratio, 
platelet count, LDH and CRP levels usually are 
economic, rapid and usable laboratory parameters that 
could straightforwardly discriminate between COVID 
patients with and without severe disease. Neutrophil 
count in severe COVID-19 cases were likely to be 
higher in contrast with lymphocyte count that were 
lower compared with non-severe patients in previous 
studies [15]. In MERS coronavirus leukocyte population 
change was found to be an important factor tied with 
severity and outcome of the patients  [16]. COVID-19 
infection causes dysregulation of immunological 
response and cytokine storm. This phenomenon 
enhances the neutrophil production and stimulates the 
lymphocyte apoptosis. On the other hand, severe viral 
infection may lead to bacterial co-infection, therefore 
neutrophil count would be raised  [15]. NLR, absolute 
neutrophil count divided by absolute lymphocyte count, 
is a simple indicator. NLR is a predictor for mortality 
in malignancies, collagen vascular diseases, infectious 
diseases, acute coronary syndrome and intracranial 
hemorrhage. A research showed that higher NLR was tied 
with mortality in admitted COVID-19 patients [17] but 
there was no association between severity of the disease 
and NLR in our study, We found that Lymphocyte count 
was lower in those who experienced severe forms of the 
disease. The decrease of Lymphocyte count might be 
explained by the following mechanisms; direct invasion 
of lymphocyte through ACE-2 receptor by virus, 
destruction of lymphoproliferative systems (Spleen, 
Thymus) by COVID-19, apoptosis of lymphocyte 
with pro-inflammatory cytokines and suppression of 
lymphocytes proliferation by lactic acidosis in severe 
infection  [18]. The present study found significant 
differences in Lymphocyte count between non-survivor 
and survivor groups (P < 0.05). Neutrophil to lymphocyte 
ratio in the survivors was less than non-survivor, however 
this difference was not significant (P > 0.05) . Platelet 
count (PLT) was significantly higher in those who had 
recovered from COVID-19 compared to those who had 
not in our study. Although, this novel coronavirus is 
Tab. I. Comparison some factors among survived and non survived cases.
Variales Total (n = 112) Survived (n = 56) Non-survived (n = 56) P-value
Age group
< 60 36 (32.1%) 17 (47.2%) 19 (52.8%)
0.68
> 60 76 (67.9%) 39 (51.3%) 37 (48.8%)
Gender
Males 77 (68.8%) 38 (50.6%) 39 (49.4%)
0.85
Females 35 (31.2%) 18 (51.4%) 17 (48.6%)
O2 status
< 93 66 (84.6%) 36 (54.5%) 30 (45.5%)
0.008
≥ 93 12 (15.4%) 12 (100%) 0(0.0%)
Comorbidity
Asthma 2 (1.8%) 0 (0.0%) 2 (100%) 0.15
Diabetes 36 (32.1%) 21 (37.5%) 15 (26.8%) 0.22
Hypertension 34 (30.4%) 19 (33.9%) 15 (26.8%) 0.411
Coronary artery disease 16 (14.3%) 6 (10.7%) 10 (17.9%) 0.28
Tab. II. Comparison of clinical and laboratory measures of survived and non-survived patients.
Variables 
Total (n = 112) Survived (n = 56) Non-survived (n = 56)
P
Mean SD Mean SD Mean SD
WBC count/ microliter 7510.18 4162.94 6470.58 3955.02 5257.14 1680.13 0.183
Neutrophil % 75.58 15.42 71.32 10.86 77.14 7.44 0.515
Lymphocyte % 17.56 8.77 22.76 11 18 7.11 0.001
Neutrophil / 
Lymphocyte
6.36 5.89 5.42 6.13 7.29 5.54 0.093
Haemoglobin (g/dL) 13.04 1.97 13.16 2.28 13.35 2.04 0.526
PLT/ microliter 191080.35 85825.73 214964.28 89961.39 167196.42 74909.01 0.003
ESR (mm/h) 66.13 29.19 60.58 23.22 58.71 27.18 0.397
CRP (mg/L) 59.32 45.06 55.5 28.63 72.85 22.31 0.101
LDH (U/L) 664.71 445.86 487.352 142.92 587.14 161.84 < 0.001
Vitamin D (ng/ml) 25.96 14.56 25.62 15.53 26.52 12.7 0.81
Blood’s oxygen 
Saturation %
86.89 9.02 91 4.01 82.42 10.46 < 0.001
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different from SARS, the mechanism of decrease in PLT 
count might be similar. Thrombocytopenia in COVID-19 
might be explained by platelet activation and aggregation 
when the virus starts immunological damage of lung 
tissue. The platelet consumption is increased in the 
injured area. Disseminated intravascular coagulopathy 
(DIC) might also be induced by COVID-19 and 
culminates in thrombocytopenia [14, 19-21]. Moreover, 
the virus may involve bone marrow directly to lead in the 
thrombocytopenia [2]. LDH is related with cytokine and 
chemokine functions. It enhances the immune responsive 
cells (e.g., CD4+ T cells) and Gamma-Interferon 
production  [22]. Suppression of LDH is linked with 
decreasing effect of the inflammatory mediators  [23]. 
Previous studies indicated that high LDH levels in some 
infection such as EBV, PCP, influenza, H1N1 and even 
Zika virus were related to lung injury [22-25]. COVID-19 
invades multiple organs (e.g., lung-intestines, liver, 
myocardium) through ACE 2 receptors. Therefore, high 
LDH level in COVID-19 patients might mean multiple 
organ damages not merely lung injury  [22-26]. Our 
research showed that the LDH levels in non-survivors are 
significantly higher than the survivor group (P < 0.005). 
It might be due to the accelerating multi-organ failure in 
the former group as compared to the latter (P < 0.001). 
COVID-19 can directly involve multiple organs, 
trigger the severe inflammatory response, and produce 
cytokines (i.e., CRP, interleukins) [22, 23]. CRP activates 
the complement system and augments phagocytosis. 
CRP attaches to virus and prompt the phagocyte cells 
to eliminate microorganisms. These molecules can 
enhance the pro-inflammatory cytokines (IL1, IL6, Il8, 
TNF-a, CRP) effects [10, 27-29]. Statistically there was 
no significant difference in CRP between survival and 
non-survival groups in our study (P = 0.101), however 
CRP was higher in those who did not survive which may 
be clinically significant and means more inflammation 
due to severe infection  [24]. The current study had 
some limitations, We focused on “death” as the index 
of severity of the disease but there are some other 
indicators such as admission in ICU that can be used 
as an indicator of severe form of the disease. Also the 
sample size in the current study was small and future 
studies are advised to evaluate the prognostic indicators 
of COVID-19 infection in larger Iranian populations. 
Conclusions
Blood oxygen saturation, LDH level, Lymphocyte count 
and PLT count are reliable, low expense biomarkers for 
monitoring COVID-19 patients’ outcome. Having these 
available biomarkers in the first day of admission, can 
be useful for early management of patients. To confirm 
these results and identification of other biomarkers in 
poor outcome patients, other studies are necessary.
The study has the following limitations. It is a unicentric 
retrospective observational study with a relatively small 
sample size. Biomarkers were measured only once at 
the time of admission, so we are unaware if the kinetics 
of biomarkers could improve or worsen the observed 
results. We provide several variables in our cohort; 
however, some variables may be missing, such as lung 
computed tomography scan information. Although viral 
presence was confirmed mainly by polymerase chain 
reaction assay, false positives and false negatives could 
be present.
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